Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions by some of India’s biggest pharma companies.
Solo venture capitalist Nathan Benaich once struggled to raise $27 million to back AI startups. His new fund is nine times as big as his first.
Anthropic’s recent dispute with the U.S. government represents an early test of how far an AI company is willing to go to control the use of its technology. Here’s what founders should take away.
AI is turning tech giants into energy companies, reshaping who builds power grid. At CERAWeek, big tech’s move into energy is taking center stage.
This week’s Current Climate newsletter also looks at a look-alike Chinese rival to Tesla’s electric Semi and facing U.S. and global water challenges
Certuma launched out of stealth with $10 million in funding from 8VC and a grand plan to make AI smart enough — and safe enough — to actually diagnose and prescribe treatments. Now he needs to figure out how to get the FDA on board.
Windrose is selling a China-built electric big rig that looks an awful lot like Tesla’s Semi. Even with import duties, CEO Wen Han says it will make money in the U.S.
How the Iran War could impact data centers. Why it’s time for nuclear microgrids. A key to breeding drought-resistant plants. All that and more in this week’s edition of The Prototype.
From everyday perks to little-known exemptions, here are 50 ways that the U.S. tax code lets you keep more of your money.
Gemini stock is down 82% from its public debut six months ago as the company reported widening losses and major business changes, prompting a lawsuit from shareholders.